Motolimod

SKU: orb1300365

Description

Motolimod (VTX-378/VTX-2337) is a potent and selective small molecule agonist of Toll-like receptor 8 (TLR8), exhibiting an EC50 of 100 nM and over 50-fold selectivity against TLR7. It is utilized in immunological research to study innate immune activation and has been investigated in preclinical models for its potential in cancer immunotherapy and as a vaccine adjuvant.

Research Area

Cell Biology, Immunology & Inflammation

Key Properties

• CAS Number: 926927-61-9
• MW: 458.61
• Purity: >98%
• Formula: C₂₈H₃₄N₄O₂
• SMILES: CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)-c1ccc(cc1)C(=O)N1CCCC1
• Target: TLR (Toll-like receptor)
• Solubility: Soluble in DMSO (up to at least 25 mg/ml)

Bioactivity

• Target IC50:
  TLR8:100 nM(EC50)
• In Vivo:
  In ovarian cancer mouse model, TX-2337 augments the effect of pegylated liposomal doxorubicin (PLD).
• In Vitro:
  Motolimodinduces the production of both TNFα (EC50: 140 nM) and IL-12 (EC50: 120 nM) in PBMCs. In mDCs and monocytes, Motolimodspecifically induces the production of IL-12 and TNFα via NF-κB activation. Motolimodalso induces IFNγ production from NK cells, enhances the lytic function of NK cells and augments ADCC.
  Read more...
• Cell Research:
  PBMCs or purified NK cells are prepared as previously described, and the purity of NK cells was approximately 99%. NK cell-mediated cytotoxicity is assessed by Calcein-AM release from labeled target cells. In brief, PBMCs or purified NK cells are cultured for 48 hours in RPMI medium in the presence of VTX-2337 (167 or 500 nmol/L) before incubation with target cells.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

VTX-2337

Compound Identifiers

PubChem CID

16049404